ArticleDiabetes2017
The Hypothalamic Glucagon-Like Peptide 1 Receptor Is Sufficient but Not Necessary for the Regulation of Energy Balance and Glucose Homeostasis in Mice.
Article in Diabetes, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Receptor Agonists: A Scoping Review.Journal of Brown hospital medicine · 2025Pooled it
- Higher semaglutide dose is associated with lower neuropsychiatric event incidence independent of weight loss.npj metabolic health and disease · 2026Article
- The central amygdala gates exogenous glucagon-like peptide 1 signals.Molecular metabolism · 2026Article
- Glucagon-like peptide-1 receptor activation and mental health: a drug-target mendelian randomization study.Translational psychiatry · 2026Article
- Beyond satiety: unraveling the complex roles of POMC neurons in behavior and metabolism.Reviews in endocrine & metabolic disorders · 2026Review
- Glucagon-Like Peptide-1 Receptor Agonists in Chronic Kidney Disease: Mechanisms and Clinical Perspectives.Kidney medicine · 2026Review
- Liraglutide reduces the apoptosis of feeding and appetite-suppressing neurons in the hypothalamus of obese rats association with the PI3K/AKT/Foxo1 pathway.Experimental brain research · 2026Article
- Glucagon-Like Peptide-1 Targets in the Human Nodose Ganglion.The Journal of comparative neurology · 2026Article
- GLP-1 physiology and pharmacology along the gut-brain axis.The Journal of clinical investigation · 2026Review
- Hesperetin and Naringenin promote glucagon-like peptide-1 secretion from L-cell through activation of TGR5 and alleviated type 2 diabetes.Frontiers in pharmacology · 2026Article
- Individual paraventricular hypothalamic GLP-1R neurons track ingestion across energy states.iScience · 2025Article
- Obesity: assessment and treatment across the care continuum.Annals of medicine · 2025Review
- Crosstalk between alcohol use disorder and obesity: two sides of the same coin?Molecular psychiatry · 2025Review
- Glucagon-Like Peptide 1 (GLP-1) Action on Hypothalamic Feeding Circuits.Endocrinology · 2025Review
- Uncovering the role of Gpr45 in obesity regulation.Molecular metabolism · 2025Article
- State-dependent central synaptic regulation by GLP-1 is essential for energy homeostasis.Nature metabolism · 2025Article
- GIPR agonism and antagonism decrease body weight and food intake via different mechanisms in male mice.Nature metabolism · 2025Article
- Glucagon-Like Peptide-1 and Hypothalamic Regulation of Satiation: Cognitive and Neural Insights from Human and Animal Studies.Diabetes & metabolism journal · 2025Review
- On the Pleiotropic Actions of Glucagon-like Peptide-1 in Its Regulation of Homeostatic and Hedonic Feeding.International journal of molecular sciences · 2025Article
- Insights into the neurobiology of weight loss after bariatric surgery and GLP-1R agonists.Neuropharmacology · 2025Review
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Pharmacological activation of the hypothalamic glucagon-like peptide 1 (GLP-1) receptor (GLP-1R) promotes weight loss and improves glucose tolerance. This demonstrates that the hypothalamic GLP-1R is sufficient but does not show whether it is necessary for the effects of exogenous GLP-1R agonists (GLP-1RA) or endogenous GLP-1 on these parameters. To address this, we crossed mice harboring floxed Glp1r alleles to mice expressing Nkx2.1-Cre to knock down Glp1r expression throughout the hypothalamus (GLP-1RKD
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.